Oncology/Hematology
Lung Cancer
More in Lung Cancer
CheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death
May 15, 2024
Study shows it may be an alternative to cancer-specific mortality for some cancers, but not all
Apr 08, 2024
About half of patients responded, duration of response as long as 19 months in three trials
Apr 05, 2024
1.00
CME Credits
0.50
CME Credits
0.25
CME Credits